会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 마이크로 RNA분자를 포함하는 항암 조성물
    • 包含微阵列分子的抗癌组合物
    • KR1020110039527A
    • 2011-04-19
    • KR1020110030405
    • 2011-04-01
    • 국립암센터
    • 박종배이승훈박은경이동희양희석유헌김혜진김태훈곽희진
    • A61K31/7105A61P35/00
    • A61K31/7105
    • PURPOSE: An anticancer composition containing micro RNA-125 nucleic acid molecule is provided to treat angiogenesis-associated diseases and to suppress cancer cell invasion and metastasis. CONSTITUTION: A composition for suppressing angiogenesis in hypoxic condition contains human-derived microRNA-125a, microRNA-125b1, or microRNA-125b2. A marker composition for diagnosing brain cancer or brain tumor contains an agent which measures microRNA-125 expression level. The microRNA-125 nucleic acid molecule suppresses cancer cell invasion and metastasis. The microRNA-125 nucleic acid molecule is used in treating angiogenesis-associated diseases, especially cancer, which are induced in hypoxia condition.
    • 目的:提供含有微RNA-125核酸分子的抗癌组合物,用于治疗血管生成相关疾病,抑制癌细胞侵袭和转移。 构成:用于抑制缺氧条件下血管发生的组合物含有人源性微RNA-125a,microRNA-125b1或microRNA-125b2。 用于诊断脑癌或脑肿瘤的标记物组合物含有测量微小RNA-125表达水平的试剂。 microRNA-125核酸分子抑制癌细胞侵袭和转移。 microRNA-125核酸分子用于治疗在缺氧条件下诱导的血管生成相关疾病,特别是癌症。
    • 3. 发明公开
    • 마이크로RNA분자를 포함하는 항암 조성물
    • 包含微阵列分子的抗癌组合物
    • KR1020100009268A
    • 2010-01-27
    • KR1020080070087
    • 2008-07-18
    • 국립암센터
    • 박종배이승훈박은경이동희양희석유헌김혜진김태훈곽희진
    • A61K31/7105A61P35/00
    • A61K31/7105
    • PURPOSE: An anti-cancer composition containing microRNA-125 nucleic acid molecule is provided to suppress infiltration and metastasis of cancer cells and angiogenesis. CONSTITUTION: An anti-cancer composition containing microRNA-125 nucleic acid molecule. The microRNA-125 is a microRNA-125a, microRNA-125b1 or microRNA-125b2 which is derived from human. The cancer is brain cancer, cervical cancer, breast cancer, bladder cancer, liver cancer, prostate cancer, and neuroblastoma. The microRNA-125 nucleic acid molecule is contained in a vector for expressing in a cell. The vector is lentivirus vector, retrovirus vector, adenovirus vector, herpersvirus vector, or avipoxvirus vector. The composition further comprises a pharmaceutically acceptable carrier. A composition for treating angiogenesis-relating disease which is induced under hypoxic condition contains the microRNA-125 nucleic acid molecule.
    • 目的:提供含有microRNA-125核酸分子的抗癌组合物,以抑制癌细胞浸润转移和血管生成。 构成:含有microRNA-125核酸分子的抗癌组合物。 microRNA-125是来自人的microRNA-125a,microRNA-125b1或microRNA-125b2。 癌症是脑癌,子宫颈癌,乳腺癌,膀胱癌,肝癌,前列腺癌和神经母细胞瘤。 微小RNA-125核酸分子包含在用于在细胞中表达的载体中。 载体是慢病毒载体,逆转录病毒载体,腺病毒载体,herpersvirus载体或avipoxvirus载体。 组合物还包含药学上可接受的载体。 用于治疗在缺氧条件下诱导的血管生成相关疾病的组合物含有微小RNA-125核酸分子。